Dr. Roth’s lab is on the cutting edge of researching the interaction between brain cell receptors and compounds like LSD and psilocybin. Their findings have the potential to revolutionize the treatment of psychiatric disorders, potentially creating new forms of psychedelics that offer the therapeutic benefits without hallucinations or other side effects.
Dr. Goriounova successfully defended her thesis, “ELD607 is a novel, specific Orai1 inhibitor,” on May 10. Her PhD Advisor was Dr. Robert Tarran.
Dr. Bryan Roth was featured in Drug Discovery and Development for his lab’s research using non-hallucinatory psychoplastogens for treating mental health disorders and on WCNC Charlotte for his advocacy for its use in clinical settings.
The lab of Juan Song, PhD, and colleagues at the UNC School of Medicine, demonstrated the therapeutic potential of new neurons generated in adulthood for modulating the pathology and functional deficits associated with Alzheimer’s disease using rodent models.
The award provides a stipend for travel expenses to the ACS Symposium in San Francisco this fall where she will present her research.
The $165K award will fund five summer researchers annually. Spearheaded by Program Director, Jonathan Schisler, the program aims to inspire undergraduate students toward careers in cardiovascular research. Becky Sanchez is Program Coordinator, Leon Coleman is an advisory board member, and Edward Bahnson’s and Brian Jensen’s labs are partners with the program.
Pharmacology graduate student Kaitlan Smith was recently awarded a diversity supplement from the National Institute on Aging (NIA) to study the effects of aging and necroptosis. She shares her resilient journey into scientific research while reflecting on her Lumbee roots.
The grant, “Observing Molecules in Context with 4Pi Lattice Light Sheet Nanoscopy,” is part of the Chan Zuckerberg Initiative’s (CZI) Dynamic Imaging projects.
The award will fund her scholarly pursuits over one year. Congratulations, Liz!
Dr. DiBerto successfully defended his thesis, “Discovery Campaigns for Pharmacologically Unique Agonists at the Mu-Opioid and 5-Hydroxytryptamine 2A Receptors on Jan. 19.”
